BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 29147860)

  • 1. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
    Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT in splenic marginal zone lymphoma.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2018 Oct; 43(10):2721-2727. PubMed ID: 29500652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary mucosa-associated lymphoid tissue lymphoma:
    Albano D; Borghesi A; Bosio G; Bertoli M; Maroldi R; Giubbini R; Bertagna F
    Br J Radiol; 2017 Nov; 90(1079):20170311. PubMed ID: 28830222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
    Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
    Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
    Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
    Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
    Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between
    Zhao J; Wang H
    J Med Imaging Radiat Oncol; 2021 Apr; 65(2):188-194. PubMed ID: 33538120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation.
    Albano D; Bosio G; Giubbini R; Bertagna F
    Leuk Lymphoma; 2017 Oct; 58(10):2328-2334. PubMed ID: 28270020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Simonitsch-Klupp I; Raderer M; Mayerhoefer ME
    Acad Radiol; 2018 Apr; 25(4):453-460. PubMed ID: 29199055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?
    Purandare NC; Puranik A; Shah S; Agrawal A; Gupta T; Moiyadi A; Shetty P; Shridhar E; Jalali R; Rangarajan V
    Nucl Med Commun; 2017 Dec; 38(12):1109-1116. PubMed ID: 28922334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Dual-Phase FDG PET/CT in the Diagnosis and Follow-Up of Brain Tumors.
    Özütemiz C; Neil EC; Tanwar M; Rubin NT; Ozturk K; Cayci Z
    AJR Am J Roentgenol; 2020 Oct; 215(4):985-996. PubMed ID: 32841063
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT and primary hepatic MALT: a case series.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2016 Oct; 41(10):1956-9. PubMed ID: 27259334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT findings in endometrial cancer patients: the correlation between SUVmax and clinicopathologic features.
    Boonya-ussadorn T; Choi WH; Hyun J; Kim SH; Chung SK; Yoo IeR
    J Med Assoc Thai; 2014 Feb; 97 Suppl 2():S115-22. PubMed ID: 25518184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.
    Ponisio MR; McConathy J; Laforest R; Khanna G
    Pediatr Radiol; 2016 Aug; 46(9):1258-68. PubMed ID: 27003132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.